

## WEST



Generate Collection

Print

L2: Entry 70 of 72

File: DWPI

Sep 5, 1995

DERWENT-ACC-NO: 1995-340208

DERWENT-WEEK: 199551

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Drug compsn. for treating animal skin diseases e.g. eczema, dermatitis - comprises mixt. of at least 2 of lactoferrin, its hydrolysed prod., peptide sepd. from hydrolysed lactoferrin, synthetic peptide and its derivs., and lacto-peroxidase.

PATENT-ASSIGNEE:

ASSIGNEE

MORINAGA MILK IND CO LTD

CODE

MORG

PRIORITY-DATA: 1994JP-0027049 (February 24, 1994)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 07233086 A	September 5, 1995		013	A61K038/44

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
JP 07233086A	February 24, 1994	1994JP-0027049	

INT-CL (IPC): A61 K 38/00; A61 K 38/16; A61 K 38/44

ABSTRACTED-PUB-NO: JP 07233086A

BASIC-ABSTRACT:

Drug compsn. comprises mixt. of at least two substances chosen from at least 3 wt.% lactoferrin, its hydrolysed product, peptide sepd. from the hydrolysed lactoferrin, synthetic peptide with identical amino acid sequence as hydrolysed lactoferrin peptide and its derivs., and 1 wt.% lactoperoxidase. Pref. the peptide with amino acid sequence No.1 to No. 31, given in the specification is used.

Drug for animal skin diseases comprises 4 to 10 wt.% of the mixture of lactoferrin, its hydrolysed products and peptides, and their peptide analogues, and 2 to 5 wt.% of lactoperoxidase.

USE/ADVANTAGE - The drug is used for treatment of eczema, urticaria, allergic dermatitis, itchy dermatitis, purulent dermatitis, skin mycosis, scabies, otitis externa and parasitic skin diseases in animals. The drug shows antimicrobial effects and causes no side effects.

In an example, 500 g lactoferrin and 300 g lactoperoxidase were dissolved in 10 litres distilled water, filtered and placed into vials (100 ml per vial).

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: DRUG COMPOSITION TREAT ANIMAL SKIN DISEASE ECZEMA DERMATITIS COMPRISE MIXTURE LACTOFERRIN HYDROLYSIS PRODUCT PEPTIDE SEPARATE HYDROLYSIS LACTOFERRIN SYNTHETIC PEPTIDE DERIVATIVE LACTO PEROXIDASE

DERWENT-CLASS: B04 D16

CPI-CODES: B04-L03B; B04-N06; B14-A04; B14-N17; B14-S12; D05-A02A;

CHEMICAL-CODES:

Chemical Indexing M2 \*02\*

Fragmentation Code

D011 D601 H1 H100 H181 J0 J014 J1 J171 J3  
J373 K0 L2 L250 M280 M312 M313 M314 M321 M332  
M343 M349 M371 M381 M391 M392 M412 M431 M511 M520  
M530 M540 M782 M903 M904 P200 P211 P330 P431 P943  
V0 V901 V902 V911 V921

Markush Compounds

199544-11416-M

Chemical Indexing M2 \*03\*

Fragmentation Code

D011 D601 H1 H100 H181 J0 J014 J1 J171 J3  
J373 K0 L2 L250 M280 M312 M313 M314 M321 M332  
M343 M349 M371 M381 M391 M392 M412 M431 M511 M520  
M530 M540 M782 M903 M904 P200 P211 P330 P431 P943  
V0 V901 V902 V911 V921

Markush Compounds

199544-11417-M

Chemical Indexing M2 \*04\*

Fragmentation Code

D011 D601 H1 H100 H181 J0 J014 J1 J171 J3  
J373 K0 L2 L250 M280 M312 M313 M314 M321 M332  
M343 M349 M371 M381 M391 M392 M412 M431 M511 M520  
M530 M540 M782 M903 M904 P200 P211 P330 P431 P943  
V0 V901 V902 V911 V921

Markush Compounds

199544-11418-M

Chemical Indexing M1 \*05\*

Fragmentation Code

M423 M431 M782 M903 P200 P211 P330 P431 P943 V0  
V802 V811 V901 V902 V911 V921

Chemical Indexing M1 \*01\*

Fragmentation Code

D011 D601 F012 F014 F423 F521 G010 G013 G100 H1  
H100 H101 H181 H182 H401 H441 H481 H498 H598 J0  
J011 J012 J1 J111 J171 J172 J371 L250 M210 M211  
M271 M280 M281 M311 M312 M313 M314 M315 M320 M321  
M331 M332 M333 M340 M342 M343 M349 M371 M381 M391  
M423 M431 M510 M511 M520 M521 M530 M531 M540 M620  
M782 M903 M904 P200 P330 P431 P943 V901 V902 V911  
V912 V913 V914 V915 V917 V921  
Markush Compounds  
199544-11401-M 199544-11402-M 199544-11403-M 199544-11404-M 199544-11405-M  
199544-11406-M 199544-11407-M 199544-11408-M 199544-11409-M 199544-11410-M  
199544-11411-M 199544-11412-M 199544-11413-M 199544-11414-M 199544-11415-M

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1995-150002

**WEST**[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
L8 and l1	2

**Database:**

[US Patents Full-Text Database](#)  
[US Pre-Grant Publication Full-Text Database](#)  
[JPO Abstracts Database](#)  
[EPO Abstracts Database](#)  
[Derwent World Patents Index](#)  
[IBM Technical Disclosure Bulletins](#)

**Search:**

L9

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**
**DATE: Sunday, May 18, 2003**   [Printable Copy](#)   [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=AND</i>			
<u>L9</u>	L8 and l1	2	<u>L9</u>
<u>L8</u>	L7 and allerg\$	11	<u>L8</u>
<u>L7</u>	5658581	15	<u>L7</u>
<u>L6</u>	L1 and antiallerg\$	9	<u>L6</u>
<u>L5</u>	L3 and l2	48	<u>L5</u>
<u>L4</u>	L3 not l2	39	<u>L4</u>
<u>L3</u>	L1 and psoriasis	87	<u>L3</u>
<u>L2</u>	L1 and dermatitis	72	<u>L2</u>
<u>L1</u>	lactoferrin	1874	<u>L1</u>

END OF SEARCH HISTORY